Literature DB >> 18978111

Influence of the time interval between hysteroscopy, dilation and curettage, and hysterectomy on survival in patients with endometrial cancer.

Lukas Hefler1, Heinz Leipold, Stefan Hinterberger, Nicole Concin, Renate Klotz, Alexander Reinthaller.   

Abstract

OBJECTIVE: To evaluate whether a prolonged time interval between dilation and curettage (D&C) and hysterectomy has an effect on survival in patients with surgically treated endometrial cancer.
METHODS: In this multicenter study, time between D&C and hysterectomy was correlated to clinical data in 344 surgically staged patients with endometrioid endometrial cancer.
RESULTS: The median (interquartile range) interval between D&amp;C and hysterectomy in patients with endometrial cancer was 23 (13-34) days. In a univariable survival analysis, International Federation of Gynecology and Obstetrics (FIGO) tumor stage (P<.001, P<.001), tumor grade (P<.001, P<.001), and patients' age (P<.001, P<.001), but not time interval from D&amp;C to hysterectomy (P=.06, P=.07) were associated with disease-free and overall survival, respectively. In a multivariable Cox regression model, FIGO tumor stage (P<.001, P<.001), and patients' age (P<.001, P<.001) but not tumor grade (P=.4, P=.2) or time interval between D&amp;C and hysterectomy (P=.5, P=.8) were independent prognostic factors for disease-free and overall survival, respectively.
CONCLUSION: We were not able to show that a prolonged time interval between D&amp;C and hysterectomy has a significant effect on the prognosis of patients with endometrial cancer. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Year:  2008        PMID: 18978111     DOI: 10.1097/AOG.0b013e31818b149f

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  1 in total

1.  Identification of risk factors for the prognosis of Chinese patients with endometrial carcinoma.

Authors:  Na Wang; Jun Zhang; Xiaomei Fan; Junying Ma; Jing He; Shan Kang; Jianxin Cheng; Jing Ma
Journal:  Medicine (Baltimore)       Date:  2021-09-24       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.